New drug combo tested for aggressive blood cancer
NCT ID NCT02717624
Summary
This early-stage study is testing whether adding a new drug called acalabrutinib to standard lymphoma treatments is safe and effective for people with mantle cell lymphoma. The trial involves 72 adults who either haven't received treatment before or whose cancer has returned. Researchers are combining acalabrutinib with two different standard drug combinations to see which works best.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Louisville, Kentucky, 40207, United States
-
Research Site
Ann Arbor, Michigan, 48109, United States
-
Research Site
Hackensack, New Jersey, 07601, United States
-
Research Site
Morristown, New Jersey, 07960, United States
-
Research Site
Lake Success, New York, 11042, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Seattle, Washington, 98109, United States
-
Research Site
Seattle, Washington, 98122, United States
-
Research Site
Bologna, 40138, Italy
-
Research Site
Krakow, 30-510, Poland
-
Research Site
Lodz, 93-510, Poland
-
Research Site
Olsztyn, 10-228, Poland
-
Research Site
Warsaw, 02-106, Poland
Conditions
Explore the condition pages connected to this study.